Neuropsychiatric lupus: Clinical challenges, brain-reactive autoantibodies and treatment strategies

Lupus

Volumn 19, Issue 12, 2010, Pages 1399-1403

  Fong, K Y ^a   Thumboo, J ^a  

^a SINGAPORE GENERAL HOSPITAL   (Singapore)

Author keywords

B cell depletion; brain reactive autoantibodies; epilepsy; psychosis; systemic lupus erythematosus

Indexed keywords

ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; AUTOANTIBODY; BRAIN REACTIVE AUTOANTIBODY; CD20 ANTIBODY; CORTICOSTEROID; CYCLOPHOSPHAMIDE; EPRATUZUMAB; GA 101; INDIAN INK; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NEUROLEPTIC AGENT; OFATUMUMAB; PHOSPHOLIPID ANTIBODY; PROTEIN ANTIBODY; RIBOSOME PROTEIN P ANTIBODY; RITUXIMAB; TRIOSEPHOSPHATE ISOMERASE ANTIBODY; UNCLASSIFIED DRUG; VELTUZUMAB;

ACANTHAMOEBA ENCEPHALITIS; ANTICOAGULANT THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; B CELL DEPLETION; B LYMPHOCYTE; BRAIN INFECTION; BRAIN RADIATION; CANCER RADIOTHERAPY; CELL SELECTION; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CRYPTOCOCCAL MENINGITIS; DISEASE ACTIVITY; DRUG INDUCED DISEASE; DRUG PULSE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRACRANIAL TUBERCULOMA; JC VIRUS; LARGE CELL LYMPHOMA; LATEX AGGLUTINATION TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR DEPRESSION; MYCOBACTERIOSIS; NEUROLOGIC DISEASE; NEUROPSYCHIATRIC LUPUS; NEUROPSYCHIATRY; PALLIATIVE THERAPY; PATHOGENESIS; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSYCHOSIS; REMISSION; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT;

AUTOANTIBODIES; B-LYMPHOCYTES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS VASCULITIS, CENTRAL NERVOUS SYSTEM; LYMPHOCYTE DEPLETION;

EID: 78649746431     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310374338     Document Type: Review

References (45)

1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25: 1271-1277.
2. Mok CC, To CH, Mak A. Neuropsychiatric damage in Southern Chinese patients with systemic lupus erythematosus. Medicine (Baltimore) 2006 ; 5: 221-228.
3. Zhou HQ, Zhang FC, Tian XP, et al. Clinical features and outcome of neuropsychiatric lupus in Chinese: analysis of 240 hospitalized patients. Lupus 2008 ; 17: 93-99.
4. Kasitanon N., Louthrenoo W., Piyasirisilp S., Sukitawu W., Wichainun R. Neuropsychiatric manifestations in Thai patients with systemic lupus erythematosus. Asian Pac J Allergy Immunol 2002 ; 20: 179-185. (Pubitemid 36253669)
5. González LA, Pons-Estel GJ, Zhang J., et al. Time to neuropsychiatric damage occurrence in LUMINA (LXVI): a multi-ethnic lupus cohort. Lupus 2009 ; 18: 822-830.
6. Mikdashi J., Handwerger B. Predictors of neuropsychiatric damage in systemic lupus erythematosus: data from the Maryland lupus cohort. Rheumatology 2004 ; 43: 1555-1560.
7. ACR Ad Hoc Committee on Neuropsychiatric Lupus Nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999 ; 42: 599-608.
8. Mak A., Chan BP, Yeh IB, et al. Neuropsychiatric lupus and reversible posterior leucoencephalopathy syndrome: a challenging clinical dilemma. Rheumatology (Oxford) 2008 ; 47: 256-262.
9. Tsang HHL, Trendell-Smith NJ, Wu AKP, Mok MY Diffuse large B-cell lymphoma of the central nervous system in mycophenolate mofetil-treated patients with systemic lupus erythematosus. Lupus 2010 ; 19: 330-333.
10. Shirwadkar CG, Samant R., Sankhe M., et al. Acanthamoeba encephalitis in patient with systemic lupus, India. Emerg Infect Dis 2006 ; 12: 984-986.
11. Hung JJ, Ou LS, Lee WI, Huang JL Central nervous system infections in patients with systemic lupus erythematosus. J Rheumatol 2005 ; 32: 40-43.
12. Sivalingam SK, Saligram P., Natanasabapathy S., Paez AS Covert cryptococcal meningitis in a patient with systemic lupus erythematous. J Emerg Med 2009 ; doi:10.1016/j.jemermed.2009.03.022.
13. Victorio-Navarra ST, Dy EE, Arroyo CG, Torralba TP Tuberculosis among Filipino patients with systemic lupus erythematosus. Semin Arthritis Rheum 1996 ; 26: 628-634.
14. Itoh K., Kano T., Nagashio C., Mimori A., Kinoshita M., Sumiya M. Progressive multifocal leukoencephalopathy in patients with systemic lupus erythematosus. Arthritis Rheum 2006 ; 54: 1020-1022.
15. Chau SY, Mok CC Factors predictive of corticosteroid psychosis in patients with systemic lupus erythematosus. Neurology 2003 ; 61: 104-107.
16. Appenzeller S., Cendes F., Costallat LT Acute psychosis in systemic lupus erythematosus. Rheumatol Int 2008 ; 28: 237-243.
17. Bachen EA, Chesney MA, Criswell LA Prevalence of mood and anxiety disorders in women with systemic lupus erythematosus. Arthritis Rheum 2009 ; 61: 822-829.
18. Chandrasekhara PK, Jayachandran NV, Rajasekhar L., Thomas J., Narsimulu G. The prevalence and associations of sleep disturbances in patients with systemic lupus erythematosus. Mod Rheumatol 2009 ; 19: 407-415.
19. Kiss E., Shoenfeld Y. Are anti-ribosomal P protein antibodies relevant in systemic lupus erythematosus? Clin Rev Allergy Immunol 2007 ; 32: 37-46. (Pubitemid 46594574)
20. Briani C., Lucchetta M., Ghirardello A., et al. Neurolupus is associated with anti-ribosomal P protein antibodies: an inception cohort study. J Autoimmun 2009 ; 32: 79-84.
21. Nery FG, Borba EF, Viana VS, et al. Prevalence of depressive and anxiety disorders in systemic lupus erythematosus and their association with anti-ribosomal P antibodies. Prog Neuropsychopharmacol Biol Psychiatry 2008 ; 32: 695-700.
22. Sherer Y., Gorstein A., Fritzler MJ, Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 2004 ; 34: 501-537.
23. Tung KS Mechanism of self-tolerance and events leading to autoimmune disease and autoantibody response. Clin Immunol Immunopathol 1994 ; 73: 275-282.
24. Hanson VG, Horowitz M., Rosenbluth D., Spiera H., Puszkin SJ Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50-kD neuronal membrane protein. J Exp Med 1992 ; 176: 565-573.
25. Bluestein HG, Zvaifler NJ Brain-reactive lymphocytotoxic antibodies in the serum of patients with systemic lupus erythematosus. J Clin Invest 1976 ; 57: 509-516.
26. Wilson HA, Winfield JB, Lahita RG, Koffler D. Association of IgG anti-brain antibodies with central nervous system dysfunction in systemic lupus erythematosus. Arthritis Rheum 1979 ; 22: 458-462.
27. Toh B., Mackay IR Autoantibody to a novel neuronal antigen in systemic lupus erythematosus and in normal human sera. Clin Exp Immunol 1981 ; 44: 555-559.
28. Hoffman SA, Arbogast DN, Ford PM, Shucard DW, Harbeck RJ Brain-reactive autoantibody levels in the sera of ageing autoimmune mice. Clin Exp Immunol 1987 ; 70: 74-83.
29. Moore PM Evidence for bound antineuronal antibodies in brains of NZB/W mice. J Neuroimmunol 1992 ; 38: 147-154.
30. Zameer A., Hoffman SA Immunoglobulin binding to brain in autoimmune mice. J Neuroimmunol 2001 ; 120: 10-18.
31. Shoenfeld Y., Lev S., Blatt I., et al. Features associated with epilepsy in the antiphospholipid syndrome. J Rheumatol 2004 ; 31: 1344-1348. (Pubitemid 38879199)
32. Bonfa E., Golombek SJ, Kaufman LD, et al. Association between lupus psychosis and antiribosomal P protein antibodies. N Engl J Med 1987 ; 317: 265-271.
33. Harris EN, Pierangeli S. Antiphospholipid antibodies and cerebral lupus. Ann N Y Acad Sci 1997 ; 823: 270-278.
34. Hirano T., Hashimoto H., Shiokawa Y., et al. Antiglycolipid autoantibody detected in the sera from systemic lupus erythematosus patients. J Clin Invest 1980 ; 66: 1437-1440.
35. Watanabe H., Seino T., Sato Y. Antibodies to triosephosphate isomerase in patients with neuropsychiatric lupus. Biochem Biophys Res Commun 2004 ; 321: 949-953.
36. Schneider AS Triosephosphate isomerase deficiency: historical perspectives and molecular aspects. Bailliere's Best Pract Res Clin Haematol 2000 ; 13: 119-140.
37. Omdal R., Brokstad K., Waterloo K., Koldingsnes W., Jonsson R., Mellgren SI Neuropsychiatric disturbances in SLE are associated with antibodies against NMDA receptors. Eur J Neurol 2005 ; 12: 392-398.
38. Tin SK, Xu Q., Thumboo J., Lee LY, Tse C., Fong KY Novel brain reactive autoantibodies: prevalence in systemic lupus erythematosus and association with psychoses and seizures. J Neuroimmunol 2005 ; 169: 153-160.
39. Hanly JG, Harrison MJ Management of neuropsychiatric lupus. Best Pract Res Clin Rheumatol 2005 ; 9: 799-821.
40. Barile-Fabris L., Ariza-Andraca R., Olguin-Ortega L., et al. Controlled clinical trial of IV cyclophosphamide versus IV methylprenisolone in severe neurological manifestations in systemic lupus erythematous. Ann Rheum Dis 2005 ; 64: 620-625.
41. Mok CC Mycophenolate mofetil for non-renal manifestations of systemic lupus erythematosus: a systematic review. Scand J Rheumatol 2007 ; 36: 9-37.
42. Nannini C., Crowson CS, Matteson EL, Moder KG Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study. Lupus 2009 ; 18: 394-399.
43. Tokunaga M., Saito K., Kawabata D., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007 ; 66: 470-475.
44. Robak E., Robak T. Monoclonal antibodies in the treatment of systemic lupus erythematosus. Curr Drug Targets 2009 ; 10: 26-37.
45. Lehnhardt FG, Scheid C., Holtik U., et al. Autologous blood stem cell transplantation in refractory systemic lupus erythematodes with recurrent longitudinal myelitis and cerebral infarction. Lupus 2006 ; 15: 240-243.